These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12380945)

  • 1. Current role of irinotecan in the treatment of non-small-cell lung cancer.
    Kelly K
    Oncology (Williston Park); 2002 Sep; 16(9):1153-62, 1165; discussion 1165-6 passim. PubMed ID: 12380945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging world role of irinotecan in lung cancer.
    Langer CJ
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):15-21. PubMed ID: 11497227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
    Adjei AA; Argiris A; Murren JR
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):32-40; discussion 41-2. PubMed ID: 10585007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
    Khuri FR
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
    Devore R; Johnson D; Crawford J; Dimery I; Eckardt J; Eckhardt SG
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):79-83. PubMed ID: 9726097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan.
    Langer CJ
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):19-24. PubMed ID: 11221017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan in cancers of the lung and cervix.
    Sandler A; van Oosterom AT
    Anticancer Drugs; 1999 Nov; 10 Suppl 1():S13-7. PubMed ID: 10630363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan in advanced lung cancer: focus on North American trials.
    Langer CJ
    Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):17-28. PubMed ID: 15255164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
    Masuda N
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan therapy for small-cell lung cancer.
    Sandler A
    Oncology (Williston Park); 2002 Apr; 16(4):419-25, 428, 433; discussion 433-4, 437-8. PubMed ID: 12017533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Camptothecin and taxane regimens for small-cell lung cancer.
    Kwong MS; Bleickardt E; Murren JR
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 9):33-8. PubMed ID: 12375799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
    J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer.
    Choy H; MacRae R
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):31-6. PubMed ID: 11221019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of irinotecan in lung cancer.
    Fukuoka M
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):6-7. PubMed ID: 11221022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer.
    Wu HG; Choy H
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 9):13-8. PubMed ID: 12375796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current status of docetaxel for advanced non-small cell lung cancer.
    Green MR
    Anticancer Drugs; 2001 Feb; 12 Suppl 1():S11-6. PubMed ID: 11340898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of topoisomerase I inhibitors in small-cell lung cancer.
    Fukuoka M
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):9-13. PubMed ID: 11497234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
    Kiura K; Takigawa N; Segawa Y; Tabata M; Shibayama T; Gemba K; Bessho A; Fujimoto N; Takata I; Hotta K; Fujiwara K; Tokuda Y; Kuyama S; Shinkai T; Ueoka H; Tanimoto M;
    J Thorac Oncol; 2007 Jan; 2(1):44-50. PubMed ID: 17410009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC.
    Choy H; Chakravarthy A; Devore RF; Jagasia M; Hande KR; Roberts JR; Johnson DH; Yunus F
    Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):43-6. PubMed ID: 10981290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions.
    Bunn PA
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-153-S12-162. PubMed ID: 9331142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.